Orbed and Corrosive-Ewing’s Sarcoma
Editorial
Ewing’s sarcoma is a commonly discerned, malignant,
paediatric bone tumour expounding as a small round cell sarcoma. Tumefaction
exhibits genetic fusions of FET family of genes, generally EWSR1 along with E26
transformation specific (ETS) family of transcription factors. Initially
scripted by James Ewing as a diffuse endothelioma of bone, Ewing’s sarcoma
exhibits diffuse membranous expression of CD99 and predominant genetic fusion
of EWSR1-FLI1. Following osteosarcoma in frequency, Ewing’s sarcoma is additionally
designated as Ewing’s sarcoma of bone, extra-skeletal Ewing’s sarcoma, or
adamantinoma-like Ewing’s sarcoma. Terminology of primitive neuro-ectodermal
tumour (PNET) or Askin tumour denominating Ewing’s sarcoma of chest wall
remains obsolete [1,2]. Ewing’s sarcoma is predominantly discerned within
Caucasian population. Children or young adults are commonly incriminated.
Majority of incriminated subjects appear <20 years and peak disease
incidence occurs within second decade. Ewing’s sarcoma is uncommonly observed
< 5 years and > 30 years. A male preponderance is observed with male to
female proportion of 1.5:1 [1,2]. Ewing’s sarcoma preponderantly incriminates
diaphysis or metaphyseal - diaphyseal region of long bones. Lower limbs, upper
limbs, ribs or pelvic bones are implicated in decreasing order of frequency. In
contrast to soft tissue, bones are commonly incriminated. Extra-skeletal
neoplasms may emerge [1,2]. Ewing’s sarcoma frequently depicts primary
chromosomal mutations which engender fusion genes between FET and ETS coterie,
features associated with modified genetic expression and enhancement of
tumorigenesis [1,2].
Additionally, secondary genomic mutations within
STAG2, CDKN2A or TP53 may be discerned. Majority of chromosomal mutations are
sporadic wherein germline mutations may ensue. Ewing’s sarcoma is possibly
engendered from mesenchymal stem cell commonly associated with chromosomal
translocations of EWSR1 and ETS partner genes [1,2]. Neoplastic cells
frequently demonstrate a genomic translocation t (11;22) (q24; q12) with
consequent emergence of EWSR1-FLI1 genetic fusion. Also, translocation t
(21;22) (q22; q12) with EWSR1-ERG genetic fusion may be discerned. Genomic
fusions of ETV1 (7p22), ETV4 (17q21) and FEV (2q35-36) are exceptional.
Infrequently discerned translocations emerge as ERG or FEV with FUS, t (16;21)
(p11;q22) FUS-ERG and t(2;16)(q35;p11) FUS-FEV. Incriminated individuals
exhibit localized pain and bony swelling. A painful, enlarging tumefaction may
be discerned with occasional pathological fracture [1,2]. Systemic features
such as fever, weight loss, anaemia, leucocytosis and elevated erythrocyte sedimentation
rate may occur [1,2]. Upon gross examination, a grey to tan tumour mass with
infiltrative perimeter is observed. Intramedullary tumefaction may exhibit
incrimination of soft tissue. Focal necrosis and hemorrhage is frequent.
‘Chemotherapy induced necrosis’ requires assessment and differentiation [1,2].
Upon frozen section, neoplasm composed of small, round blue cells is observed.
Cytological evaluation of Ewing’s sarcoma exhibits uniform, small round cells
imbued with scanty, indistinct cytoplasm, finely dispersed nuclear chromatin
and occasional nucleoli. Rosette-like configurations are infrequent [1,2]. Upon
microscopy, Ewing’s sarcoma defines diverse variants as
• Classical Ewing’s sarcoma exhibits a sheet-like
tumour configuration or islands of tumour cells segregated by dense, fibrous
tissue septa. Tumefaction is constituted of uniform small round cells
incorporated with spherical nuclei, finely stippled chromatin, inconspicuous
nucleoli and scanty, clear to eosinophilic cytoplasm with indistinct
cytoplasmic boundaries [1,2].
• Ewing’s sarcoma with neuro-ectodermal differentiation demonstrates
Homer-Wright pseudo-rosettes.
• Atypical Ewing’s sarcoma delineates tumour cells with enlarged nuclei,
irregular nuclear contour, vesicular or coarse chromatin and prominent
nucleoli.
• Adamantinoma-like Ewing’s sarcoma is a high-grade neoplasm which enunciates
nests of basaloid cells with minimal pleomorphism, peripheral nuclear
palisading and cording. Surrounding stroma is predominantly myxoid, fibro
myxoid or hyalinized. Foci of keratinous pearls are discerned [1,2] (Figures 1
& 2).
Figure 1.
• Ewing’s sarcoma with neuro-ectodermal differentiation demonstrates Homer-Wright pseudo-rosettes.
• Atypical Ewing’s sarcoma delineates tumour cells with enlarged nuclei, irregular nuclear contour, vesicular or coarse chromatin and prominent nucleoli.
• Adamantinoma-like Ewing’s sarcoma is a high-grade neoplasm which enunciates nests of basaloid cells with minimal pleomorphism, peripheral nuclear palisading and cording. Surrounding stroma is predominantly myxoid, fibro myxoid or hyalinized. Foci of keratinous pearls are discerned [1,2] (Figures 1 & 2).
Figure 2.
TNM Staging
of Ewing’s Sarcoma, Contingent to American Joint Committee on Cancer, Eight
Edition Is Denominated As
• Stage I remains non applicable as Ewing’s sarcoma
is a high-grade tumefaction of Grade II or Grade III category.
• Stage II is subdivided into
i. ~stage IIA demonstrates a high grade, intracompartmental tumour ≤ 8
centimeters diameter. Regional lymph node or distant metastasis is absent. ii.
~stage IIB demonstrates a high-grade tumour > 8 centimetre magnitude devoid
of regional lymph node or distant metastasis.
• Stage III demonstrates a high grade, extra-compartmental or a multi-centric
tumour incriminating a singular bone. Neoplasm is devoid of regional lymph node
or distant metastasis.
• Stage IV is subdivided into
i. ~stage IVA delineates a tumefaction of variable magnitude with pulmonary
metastasis. Metastasis to regional lymph nodes or diverse organs is absent.
• Stage IVB exhibits a tumefaction of variable magnitude with tumour metastasis
into regional lymph nodes. Distant metastasis may or may not be observed.
Pulmonary metastasis is absent [2,3].
Additional
Categories Are Denominated As
• TX: Primary tumour cannot be assessed.
• T0: No evidence of primary tumour.
• NX: Regional lymph nodes cannot be assessed.
Tumour
Grading Is Expounded As
• Grade 1: Gradually progressive tumour simulates
normal cells.
• Grade 2: Tumour cells appear malignant and abnormal.
• Grade 3: Tumour cells appear extremely anomalous, malignant and disseminate
rapidly [2,3].
Ewing’s
Sarcoma May Manifest As a
• Localized tumefaction wherein tumour is confined
to singular tissue of tumour induction as bone or skeletal muscle. Regional
lymph nodes may be implicated. Distant metastases are absent although miniature
aggregates of neoplastic cells may disseminate to diverse organs [2,3].
• Metastatic tumefaction depicting tumour dissemination into diverse organs or
viscera as lungs, various bones, or bone marrow. Metastasis into regional lymph
nodes or hepatic parenchyma is infrequent [2,3].
• Low grade, localized neoplasm delineates stage I
• High grade, localized neoplasm exemplifies stage II
• Metastatic neoplasm enunciates grade III, irrespective of tumour grade.
Aforesaid staging is not applicable to neoplasms
emerging with pelvic bones or vertebral column [2,3]. Ewing’s sarcoma is immune
reactive to CD99, NKX2.2, vimentin, FLI1, ERG, cytokeratin, NSE, p63 or p40.
Glycogen rich tumour cells can be stained with Periodic acid- Schiff’s stain
with sensitivity to diastase. Ewing’s sarcoma is immune non-reactive to LCA or
CD45, desman, myogenic, MyoD1, WT1, ETV6, CIC, BCOR, CCNB3, SATB2, SOX9, NUT1,
TTF1, chromogranin, TdT, S100 protein, synaptophysin, NCAM, or cytokeratin
[3,4]. Ewing’s sarcoma requires segregation from neoplasms such as mesenchymal
chondrosarcoma, metastatic neoplasms composed of small round cell morphology as
neuroblastoma, alveolar rhabdomyosarcoma, primary lymphoma of bone, small cell
osteosarcoma, poorly differentiated synovial sarcoma, neuro-ectodermal tumours,
CIC rearranged sarcoma, BCOR rearranged sarcoma, round cell sarcoma with
EWSR1-non ETS fusion, desmoplastic small round cell tumour, basaloid squamous
cell carcinoma or high grade neuroendocrine carcinoma (adamantinoma-like
variant). Besides, osteomyelitis or eosinophilic granuloma necessitates
demarcation. Ewing’s sarcoma can be appropriately discerned with amalgamation
of clinical, radiographic, and molecular characterization along with pertinent
immunohistochemistry. Features of a small, round cell tumefaction with diffuse,
membranous CD99 expression and genomic fusion of FET-ETS genes is diagnostic
[3,4]. Incriminated subjects depict anemia, leukocytosis and elevated
erythrocyte sedimentation rate [3,4]. Plain radiographs manifest an osteolytic
lesion with bone permeation, inadequately defined lesion perimeter, foci of
‘moth eaten’ bone destruction, aggressive periosteal reaction with occurrence
of ‘onion skin’ appearance or a ‘sunburst’ periosteal reaction and
saucerization or extra-osseous tumour extension and bone erosion [3,4].
Configuration of tumour osteoid or matrix is absent. Ascertainment of tumour
extent upon plain radiography can be challenging [3,4]. Computerized
tomography, magnetic resonance imaging or positron emission computerized
tomography can be adopted to appropriately define primary lesion, assess tumour
extension into surrounding soft tissue and metastatic disease [3,4].
T1 weighted magnetic resonance imaging depicts
minimal to intermediate signal intensity. T2 weighted imaging delineates a
heterogeneous, predominantly enhanced signal intensity. Ewing’s sarcoma can be
optimally treated with neoadjuvant chemotherapy followed by surgical
intervention [3,4]. Pertinent chemotherapeutic protocol for Ewing’s sarcoma is
alternating vincristine / doxorubicin / cyclophosphamide and ifosfamide /
etoposide which ameliorates prognostic outcomes [3,4]. Radiotherapy is
preferably adopted for treating surgically inaccessible neoplasms,
unsatisfactory tumour eradication from excised tissue perimeter and as a
palliative therapy. Immunotherapy exhibits limited efficacy [3,4]. Prognostic
outcomes are contingent to appearance of regional lymph node or distant
metastases. Localized disease subjected to cogent surgical resection exhibits
favourable 5-year disease survival. Neoplasms associated with distant
metastasis enunciate inferior 5-year disease survival [3,4]. Surgical
extermination of pulmonary metastases ameliorates individual survival [3,4].
Factors associated with favourable prognostic outcomes are comprehensive
pathologic response to neoadjuvant chemotherapy, miniature neoplasms confined
to superficial sites and tumour confined to sites accessible to surgical
extermination [3,4]. Factors associated with unfavorable prognostic outcomes
are preliminary tumour relapse, occurrence of distant metastasis and neoplasms
confined to anatomical sites as trunk or pelvis [3-6].
Follow us for more Articles on: https://biomedres01.blogspot.com/
https://scholar.google.com/citations?user=OFtUOZYAAAAJ&hl=en
https://www.base-search.net/Search/Results?lookfor=Biomed+Journal+of+Scientific+%26+Technical+Research&l=en&refid=dcsuggesten
https://citefactor.org/journal/2574-1241/biomedical-journal-of-scientific-technical-research
https://ideas.repec.org/s/abf/journl.html
https://econpapers.repec.org/article/abfjournl/
https://www.ncbi.nlm.nih.gov/nlmcatalog/101723284
https://bjstr.org/
https://bjstr.org/about.php
https://biomedres.us/reprints.php
https://biomedres.net/submit-manuscript.php
https://independent.academia.edu/BJSTRAngelaRoy

















